Sun Pharmaceutical Industries Limited Stock Price Today (NSE: SUNPHARMA)
Fundamental Score
Sun Pharmaceutical Industries Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Sun Pharmaceutical Industries Limited share price today is ₹1875.10, down 2.84% on NSE/BSE as of 24 August 2026. Sun Pharmaceutical Industries Limited (SUNPHARMA) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹4.69L (Cr). The 52-week high for SUNPHARMA share price is ₹2046.90 and the 52-week low is ₹1548.00. At a P/E ratio of 37.73x, SUNPHARMA is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 15.95% and a debt-to-equity ratio of 0.06.
Sun Pharmaceutical Industries Limited Share Price Chart — NSE/BSE Historical Performance
Sun Pharmaceutical Industries Limited share price chart: 0.65% return over the past month. 52-week high ₹2046.90, 52-week low ₹1548.00.
Sun Pharmaceutical Industries Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1890.00 | ₹1899.00 | ₹1868.30 | ₹1875.10 | 18.19L (Cr) | |
| ₹1932.00 | ₹1937.00 | ₹1914.70 | ₹1930.00 | 8.81L (Cr) | |
| ₹1943.00 | ₹1946.30 | ₹1931.10 | ₹1932.00 | 12.16L (Cr) | |
| ₹1942.00 | ₹1945.70 | ₹1926.80 | ₹1944.00 | 15.36L (Cr) | |
| ₹1939.00 | ₹1951.10 | ₹1928.60 | ₹1942.00 | 21.26L (Cr) | |
| ₹1949.90 | ₹1965.00 | ₹1939.80 | ₹1944.40 | 17.27L (Cr) | |
| ₹1955.00 | ₹1957.00 | ₹1925.10 | ₹1945.00 | 24.25L (Cr) | |
| ₹1930.00 | ₹1965.90 | ₹1930.00 | ₹1951.00 | 18.65L (Cr) | |
| ₹1967.80 | ₹1968.20 | ₹1934.00 | ₹1940.00 | 21.53L (Cr) | |
| ₹1951.10 | ₹1965.00 | ₹1947.00 | ₹1964.00 | 14.53L (Cr) |
Sun Pharmaceutical Industries Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1983.20 | ₹1988.00 | ₹1868.30 | ₹1875.10 | -5.45% | |
| ₹1877.90 | ₹2046.90 | ₹1860.20 | ₹1990.50 | +6.00% | |
| ₹1812.00 | ₹1902.40 | ₹1756.80 | ₹1862.50 | +2.79% | |
| ₹1820.00 | ₹1916.60 | ₹1785.30 | ₹1799.20 | -1.14% | |
| ₹1762.10 | ₹1815.00 | ₹1613.60 | ₹1808.30 | +2.62% | |
| ₹1712.00 | ₹1843.00 | ₹1712.00 | ₹1757.20 | +2.64% | |
| ₹1634.00 | ₹1792.20 | ₹1598.20 | ₹1737.00 | +6.30% | |
| ₹1720.00 | ₹1806.60 | ₹1583.70 | ₹1595.30 | -7.25% | |
| ₹1841.00 | ₹1849.00 | ₹1707.00 | ₹1719.70 | -6.59% | |
| ₹1688.20 | ₹1833.00 | ₹1667.00 | ₹1831.60 | +8.49% | |
| ₹1611.90 | ₹1722.00 | ₹1600.00 | ₹1690.70 | +4.89% | |
| ₹1599.00 | ₹1668.10 | ₹1548.00 | ₹1594.30 | -0.29% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Sun Pharmaceutical Industries Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Sun Pharmaceutical Industries Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SUNPHARMA across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (15.95%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (20.53%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (27.49%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Excellent EPS Growth (16.75% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (16.75% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.06)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (49.49x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 2.89)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹41319.33 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (54.48%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 36.94%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Risk Factors
1 factors identified
High Price-to-Book Ratio (6.23x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Sun Pharmaceutical Industries Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Sun Pharmaceutical Industries Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti...Selected✓ SUNPHARMA • 524715 | 66.4/100 | ₹1875.10₹1875 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹7386.50₹7387 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1415.10₹1415 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Biocon LtdBiocon Ltd... BIOCON • 532523 | 30.2/100 | ₹437.95₹438 | ₹70826.50₹70826.50 | 181.85Average 181.8 Average | 1.40%Poor 1.40% Poor | 3.75%Poor 3.75% Poor | 0.45Excellent 0.5 Excellent | -11.84%Poor -11.84% Poor | 18.83%Excellent 18.83% Excellent | 0.12% |
Abbott India LtdAbbott India Lt... ABBOTINDIA • 500488 | 62.3/100 | ₹28900.00₹28900 | ₹58692.31₹58692.31 | 37.82Average 37.8 Average | 34.46%Excellent 34.46% Excellent | 44.89%Excellent 44.89% Excellent | 0.04Excellent 0.0 Excellent | 17.57%Excellent 17.57% Excellent | 9.96%Good 9.96% Good | 1.90% |
JB Chemicals & Pharmaceuticals LtdJB Chemicals & ... JBCHEPHARM • 506943 | 53.9/100 | ₹2408.90₹2409 | ₹40248.14₹40248.14 | 56.02Average 56.0 Average | 18.93%Good 18.93% Good | 25.45%Excellent 25.45% Excellent | 0.00Excellent 0.0 Excellent | 12.37%Good 12.37% Good | 15.22%Excellent 15.22% Excellent | 0.88% |
Wockhardt LtdWockhardt Ltd... WOCKPHARMA • 532300 | 24.6/100 | ₹1953.40₹1953 | ₹30725.07₹30725.07 | 108.16Average 108.2 Average | 6.11%Poor 6.11% Poor | 7.55%Poor 7.55% Poor | 0.45Excellent 0.5 Excellent | -19.25%Poor -19.25% Poor | 4.49%Average 4.49% Average | 0.00% |
ACUTAAS CHEMICALS LIMITEDACUTAAS CHEMICA... ACUTAAS • 543349 | 62.09999999999999/100 | ₹3659.60₹3660 | ₹29036.77₹29036.77 | 81.50Average 81.5 Average | 24.05%Excellent 24.05% Excellent | 31.56%Excellent 31.56% Excellent | 0.02Excellent 0.0 Excellent | 45.77%Excellent 45.77% Excellent | 31.50%Excellent 31.50% Excellent | 0.04% |
Sequent Scientific LtdSequent Scienti... SEQUENT • 512529 | 63.9/100 | ₹188.78₹189 | ₹12241.20₹12241.20 | 61.29Average 61.3 Average | 11.05%Average 11.05% Average | 19.05%Good 19.05% Good | 0.17Excellent 0.2 Excellent | 15.00%Excellent 15.00% Excellent | 20.23%Excellent 20.23% Excellent | 0.00% |
Aarti Pharmalabs LtdAarti Pharmalab... AARTIPHARM • 543748 | 9.1/100 | ₹672.70₹673 | ₹6511.24₹6511.24 | 36.83Average 36.8 Average | 8.59%Poor 8.59% Poor | 10.70%Average 10.70% Average | 0.36Excellent 0.4 Excellent | — — | — — | 0.70% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Divis Laboratories Ltd share price193163.97 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
- Biocon Ltd share price70826.50 Cr
- Abbott India Ltd share price58692.31 Cr
Sun Pharmaceutical Industries Limited PE Ratio History
Historical price-to-earnings ratio for SUNPHARMA — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹45.60 | ₹1719.70 | 37.7x |
| FY 2024 | ₹39.90 | ₹1886.35 | 47.3x |
| FY 2023 | ₹35.30 | ₹1259.45 | 35.7x |
| FY 2022 | ₹13.60 | ₹1001.40 | 73.6x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Sun Pharmaceutical Industries Limited Dividend History
Annual cash dividends paid by SUNPHARMA — dividend yield 0.82%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹3613.97 Cr |
| FY 2024 | ₹2898.17 Cr |
| FY 2023 | ₹2518.88 Cr |
| FY 2022 | ₹2158.92 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Sun Pharmaceutical Industries Limited Quarterly Performance
Latest quarterly metrics for SUNPHARMA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
12.76%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
13.58%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
11.78%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
16.75%
Compounded annual net profit growth over 5 years
Sun Pharmaceutical Industries Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for SUNPHARMA — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Sun Pharmaceutical Industries Limited Financial Statements
Annual income statement, balance sheet and cash flow for Sun Pharmaceutical Industries Limited (SUNPHARMA) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Sun Pharmaceutical Industries Limited
About SUNPHARMA (Sun Pharmaceutical Industries Limited)
Sun Pharmaceutical Industries Ltd. is a global pharmaceutical powerhouse, forging a path of innovation and accessibility in the healthcare landscape. Emerging from humble beginning...s, the company has evolved into a leading entity, dedicated to the development, manufacturing, and distribution of a wide array of pharmaceutical products. Sun Pharma's unwavering commitment to research and development fuels the creation of novel formulations and therapeutic solutions, addressing critical medical needs across diverse populations. The company operates with a core philosophy of making high-quality medicines available and affordable, ensuring that healthcare reaches a broader spectrum of individuals, globally. The bedrock of Sun Pharma's success lies in its expansive portfolio, which encompasses both branded and generic medications, alongside a robust production of active pharmaceutical ingredients (APIs). This diversified approach allows the company to cater to a multitude of medical conditions, offering effective treatments for ailments affecting various systems within the human body. From central nervous system disorders and cardiovascular issues to metabolic diseases and gastrointestinal complications, Sun Pharma provides solutions in a range of therapeutic areas. Furthermore, its specialized focus on areas such as dermatology, ophthalmology, and oncology highlights the company's commitment to addressing complex and specialized healthcare challenges. Sun Pharma's global footprint is a testament to its ambition and strategic vision, with a significant presence in key markets like India and the United States, as well as an expanding reach across international territories. This expansive network enables the company to efficiently distribute its products, ensuring that healthcare providers and patients have access to the medicines they require. Through strategic partnerships, acquisitions, and a dedication to quality manufacturing practices, Sun Pharma continues to strengthen its position as a global leader in the pharmaceutical industry, driven by a desire to improve lives and make a meaningful contribution to global health.
Company Details
Key Leadership
Corporate Events
Latest News
SUNPHARMA Share Price: Frequently Asked Questions
What is the current share price of Sun Pharmaceutical Industries Limited?
Sun Pharmaceutical Industries Limited (SUNPHARMA) trades at ₹1875.10 on NSE and BSE. Market cap ₹4.69L (Cr). Educational data only.
What is the P/E ratio of Sun Pharmaceutical Industries Limited?
Sun Pharmaceutical Industries Limited has a P/E of 37.73x vs industry average 34.89x.
What is the Bull Run score for Sun Pharmaceutical Industries Limited?
Sun Pharmaceutical Industries Limited has a Bull Run score of 66.4/100 based on 25+ financial parameters.
Does Sun Pharmaceutical Industries Limited pay dividends?
Sun Pharmaceutical Industries Limited has a dividend yield of 0.82%. Past dividends don't guarantee future payments.
What is the ROE of Sun Pharmaceutical Industries Limited?
Sun Pharmaceutical Industries Limited has ROE of 15.95%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Sun Pharmaceutical Industries Limited?
Sun Pharmaceutical Industries Limited has debt-to-equity of 0.06.
Is Sun Pharmaceutical Industries Limited a good investment?
Bull Run gives Sun Pharmaceutical Industries Limited a score of 66.4/100. This is not investment advice — consult a SEBI-registered advisor.